Alumis New Phase 3 ONWARD Data Show Envudeucitinib Improved Scalp, Itch And Quality Of Life In Psoriasis, Building On 54% PASI 100 At Week 48; NDA On Track For 4Q 2026

Alumis reported positive Phase 3 ONWARD data for envudeucitinib, showing a 54% complete skin clearance (PASI 100) at Week 48, indicating its potential as a leading oral therapy for moderate-to-severe plaque psoriasis. Patients switching from placebo or apremilast experienced rapid responses similar to those on continuous treatment. The company is on track to submit a New Drug Application (NDA) for envudeucitinib in the fourth quarter of 2026.